Elevation Oncology Cash And Equivalents vs. Return On Asset

ELEV Stock  USD 0.64  0.02  3.23%   
Based on the key profitability measurements obtained from Elevation Oncology's financial statements, Elevation Oncology may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Elevation Oncology's ability to earn profits and add value for shareholders. At this time, Elevation Oncology's Price Earnings To Growth Ratio is fairly stable compared to the past year. Company Equity Multiplier is likely to climb to 1.71 in 2024, whereas Free Cash Flow Yield is likely to drop (3.22) in 2024.
For Elevation Oncology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Elevation Oncology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Elevation Oncology utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Elevation Oncology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Elevation Oncology over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities.
For more information on how to buy Elevation Stock please use our How to Invest in Elevation Oncology guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Elevation Oncology. If investors know Elevation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Elevation Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.80)
Return On Assets
(0.25)
Return On Equity
(0.64)
The market value of Elevation Oncology is measured differently than its book value, which is the value of Elevation that is recorded on the company's balance sheet. Investors also form their own opinion of Elevation Oncology's value that differs from its market value or its book value, called intrinsic value, which is Elevation Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Elevation Oncology's market value can be influenced by many factors that don't directly affect Elevation Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Elevation Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Elevation Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Elevation Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Elevation Oncology Return On Asset vs. Cash And Equivalents Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Elevation Oncology's current stock value. Our valuation model uses many indicators to compare Elevation Oncology value to that of its competitors to determine the firm's financial worth.
Elevation Oncology is rated # 2 in cash and equivalents category among its peers. It also is rated # 2 in return on asset category among its peers . Return On Assets is likely to drop to -0.54 in 2024. Comparative valuation analysis is a catch-all technique that is used if you cannot value Elevation Oncology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Elevation Return On Asset vs. Cash And Equivalents

Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Elevation Oncology

Cash

 = 

Bank Deposits

+

Liquidities

 = 
122.54 M
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Elevation Oncology

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.25
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Elevation Return On Asset Comparison

Elevation Oncology is currently under evaluation in return on asset category among its peers.

Elevation Oncology Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Elevation Oncology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Elevation Oncology will eventually generate negative long term returns. The profitability progress is the general direction of Elevation Oncology's change in net profit over the period of time. It can combine multiple indicators of Elevation Oncology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive IncomeK9.4 K
Operating Income-45.4 M-47.7 M
Income Before Tax-45.7 M-48 M
Total Other Income Expense Net-229 K-240.4 K
Net Loss-85.6 M-81.3 M
Net Loss-45.7 M-48 M
Income Tax Expense30 K31.5 K
Net Loss-56.8 M-59.7 M
Net Interest Income-300 K-315 K
Interest Income3.9 M2.7 M
Non Operating Income Net Other-455.4 K-478.2 K
Change To NetincomeM4.2 M
Net Loss(1.34)(1.41)
Income Quality 1.23  0.75 
Net Income Per E B T 1.00  0.80 

Elevation Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Elevation Oncology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Elevation Oncology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Elevation Oncology's important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Elevation Oncology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Diagnostics Now

   

Portfolio Diagnostics

Use generated alerts and portfolio events aggregator to diagnose current holdings
All  Next Launch Module

Use Investing Themes to Complement your Elevation Oncology position

In addition to having Elevation Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Heavy Metals Thematic Idea Now

Heavy Metals
Heavy Metals Theme
Companies involved in mining, production, and distribution of various industrial metals and minerals. The Heavy Metals theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Heavy Metals Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Elevation Stock Analysis

When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.